EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Probiotic Sources: 14

Streptococcus salivarius K12

Also called: S. salivarius K12, SsK12, Streptococcus salivarius strain K12

Streptococcus salivarius K12 is an oral probiotic strain of a species that is a predominant member of the human oropharynx. It produces two lantibiotic bacteriocins, salivaricin A2 and salivaricin B, encoded on a 190-kb megaplasmid. Results here are for K12.

Category
Probiotic
Forms
Live bacteria in lozenges, chewable tablets or oral powder sachets; amounts stated in CFU
Strongest evidence
C Limited
Reviewed
2026-10-30

Class 1 Well studied in people. A 2019 systematic review identified 4 RCTs (1,846 participants) of K12 for sore throat, all rated poor quality. We confirmed 7 further randomized trials of K12 alone versus placebo (2011–2024): otitis media, oral mucositis, halitosis, respiratory infections, salivary IgA (two) and tolerance. [3]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

5 topics studied4 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Streptococcus salivarius K12 does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Streptococcus salivarius K12, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Sore throat (pharyngotonsillitis) in children and adultsCA 2019 systematic review found 4 RCTs (1,846 participants), all poor quality: two child trials versus no treatment reported benefit (pharyngitis, adenoiditis), a 1,314-child placebo trial found none, and an adult trial alongside penicillin showed none. [3]
Acute otitis media in children attending day careXIn a double-blind RCT of 827 children aged 1–6 years, 6 months of K12 (1 x 10^9 CFU/day) did not reduce otitis media needing antimicrobial therapy (8.2% vs 5.8% with placebo). [4]
Severe oral mucositis during head and neck radiotherapyCIn a double-blind RCT of 160 patients, K12 lozenges three times daily during radiotherapy lowered the incidence of severe oral mucositis (36.6% vs 54.2%) and shortened its duration versus placebo. [5]
Halitosis associated with tongue coatingCIn an RCT of 28 adults, 30 days of K12 tablets without prior tongue-coating removal did not differ from placebo in breath odor scores, volatile sulfur compounds or tongue coating. [6]
Upper respiratory infections in physically active young adultsCIn a double-blind RCT of 112 adults aged 19–25, symptom severity did not differ from placebo over four months; participants with over 90% adherence reported more symptom-free days. [7]

Main constituents: Salivaricin A2 (2,368 Da) and salivaricin B (2,740 Da), lantibiotic bacteriocins encoded on the 190-kb megaplasmid pSsal-K12 [2]; S. salivarius is naturally a predominant member of the human oropharynx [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Otitis media trial: 1 x 10^9 CFU K12 once daily (oral powder sachet under age 3, chewable tablet from age 3) for 6 months. [4]
  • Oral mucositis trial: K12 lozenges sucked three times daily from the start to the end of radiotherapy. [5]
  • Tolerance trial: 1 x 10^10 CFU/day for 28 days in adults. [1]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • In a randomized double-blind trial of 53 adults, 1 x 10^10 CFU/day for 28 days caused no differences from placebo in blood chemistry, hematology or adverse events. [1]
  • In all four sore-throat RCTs, K12 was safe and well tolerated. [3]
  • In the radiotherapy trial, adverse events were similar between groups; two patients had mild or moderate flatulence or dyspepsia linked to the lozenges. [5]
  • FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [10]
  • ODS (probiotics in general): probiotics may cause harm in certain populations, including people who are severely ill or immunocompromised. [10]
Quality

Identity, quality and standardization

  • The salivaricin A2 and B genes sit on pSsal-K12, a 190-kb transmissible megaplasmid. [2]
  • US labels must list total microorganism weight, which can include live and dead cells; CFU may be listed voluntarily. [10]
Regulation

Regulatory status

  • Canada: Streptococcus salivarius is listed in Appendix I (Table 6) of Health Canada's probiotics monograph (April 24, 2026) as excluded from the monograph and its compendial application process. [11]
  • US: No NDI notification naming Streptococcus salivarius K12 was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [12]
  • US: FDA's GRAS Notice Inventory lists GRN 591 (S. salivarius K12 in foods including medical foods, at up to 20 mg per serving providing at least 2 x 10^9 CFU); FDA's letter (closed January 25, 2016): 'FDA has no questions'. [13]
  • US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [14]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Live Streptococcus salivarius K12 Oral probiotic bacterium (genus Streptococcus) [P1]
  • Salivaricin A2 and salivaricin B Lantibiotic bacteriocins (peptides) [P2]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming Streptococcus salivarius K12 was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]
  • FDA's GRAS Notice Inventory lists GRN 591 (S. salivarius K12 in foods including medical foods, at up to 20 mg per serving providing at least 2 x 10^9 CFU); FDA's letter (closed January 25, 2016): 'FDA has no questions'. [P4]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of Streptococcus salivarius K12 was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P5]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P7]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Burton JP, et al. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol 2011;49(9):2356-64 (PMID 21722694), 2011-09. pubmed.ncbi.nlm.nih.gov
  2. Hyink O, et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 2007;73(4):1107-13 (PMID 17194838), 2007-02. pubmed.ncbi.nlm.nih.gov
  3. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  4. FDA. GRAS Notice Inventory: GRN No. 591, Streptococcus salivarius K12 (date of closure Jan 25, 2016), 2016-01-25. hfpappexternal.fda.gov
  5. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  6. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
  7. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources

Sources

  1. Burton JP, et al. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol 2011;49(9):2356-64 (PMID 21722694), 2011-09. pubmed.ncbi.nlm.nih.gov
  2. Hyink O, et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 2007;73(4):1107-13 (PMID 17194838), 2007-02. pubmed.ncbi.nlm.nih.gov
  3. Wilcox CR, et al. Effectiveness of the probiotic Streptococcus salivarius K12 for the treatment and/or prevention of sore throat: a systematic review. Clin Microbiol Infect 2019;25(6):673-680 (PMID 30616011), 2019-06. pubmed.ncbi.nlm.nih.gov
  4. Sarlin S, et al. Streptococcus salivarius probiotics to prevent acute otitis media in children: a randomized clinical trial. JAMA Netw Open 2023;6(11):e2340608 (PMID 37917062), 2023-11-01. pubmed.ncbi.nlm.nih.gov
  5. Peng X, et al. Streptococcus salivarius K12 alleviates oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors: a randomized controlled trial. J Clin Oncol 2024;42(12):1426-1435 (PMID 38215354), 2024-04-20. pubmed.ncbi.nlm.nih.gov
  6. He L, et al. The effect of Streptococcus salivarius K12 on halitosis: a double-blind, randomized, placebo-controlled trial. Probiotics Antimicrob Proteins 2020;12(4):1321-1329 (PMID 32227309), 2020-12. pubmed.ncbi.nlm.nih.gov
  7. Bertuccioli A, et al. Efficacy of Streptococcus salivarius Blis K12 in the prevention of upper respiratory tract infections in physically active individuals: a randomized controlled trial. Microorganisms 2024;12(11):2164 (PMID 39597553), 2024-10-26. pubmed.ncbi.nlm.nih.gov
  8. Bertuccioli A, et al. Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: a randomised double-blind study. Front Immunol 2023;14:1129060 (PMID 36936914), 2023-03-02. pubmed.ncbi.nlm.nih.gov
  9. Babina K, et al. The effect of oral probiotics (Streptococcus salivarius k12) on the salivary level of secretory immunoglobulin A, salivation rate, and oral biofilm: a pilot randomized clinical trial. Nutrients 2022;14(5):1124 (PMID 35268099), 2022-03-07. pubmed.ncbi.nlm.nih.gov
  10. NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
  11. Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
  12. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  13. FDA. GRAS Notice Inventory: GRN No. 591, Streptococcus salivarius K12 (date of closure Jan 25, 2016), 2016-01-25. hfpappexternal.fda.gov
  14. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in probiotic: Akkermansia muciniphila (pasteurized) · Bacillus coagulans (Heyndrickxia coagulans) · Bifidobacterium animalis subsp. lactis BB-12 · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus paracasei strain Shirota (LcS) · Lacticaseibacillus rhamnosus GG (LGG) · Lactiplantibacillus plantarum 299v · Limosilactobacillus reuteri DSM 17938 · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.